Accuracy of MRI in the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy
Eric L. Rosen1,
Kimberly L. Blackwell2,
Jay A. Baker1,
Mary Scott Soo1,
Rex C. Bentley3,
Daohai Yu4,
Thaddeus V. Samulski5 and
Mark W. Dewhirst6
1 Department of Radiology, Breast Imaging Division, Box 3808, Duke University
Medical Center, Durham, NC 27710.
2 Department of Medicine, Oncology Division, Box 3893, Duke University Medical
Center, Durham, NC 27710.
3 Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC
27710.
4 Department of Biostatistics and Bioinformatics, Box 3958, Duke University
Medical Center, Durham, NC 27710.
5 Department of Radiation Oncology, Radiation Physics Division, Box 3085, Duke
University Medical Center, Durham, NC 27710.
6 Department of Radiation Oncology, Box 3455, Duke University Medical Center,
Durham, NC 27710.

View larger version (15K):
[in a new window]
|
Fig. 1. Graph shows relationship between data points ( =
physical examination, = MRI) and best-fit line between MRI, physical
examination, and histology. Solid line = identity, dashed line = MRI, dotted
line = physical examination.
|
|

View larger version (15K):
[in a new window]
|
Fig. 2A. Graphs show difference between histology and physical
examination or MRI plotted against mean of histology and physical examination
or MRI. Solid line = identity, dashed line = histologyphysical
examination. Difference in tumor size at histology and on physical examination
increases with increasing tumor size, suggesting that physical examination
becomes more inaccurate as tumor size increases, particularly when size of
residual tumor exceeds 5 cm.
|
|

View larger version (13K):
[in a new window]
|
Fig. 2B. Graphs show difference between histology and physical
examination or MRI plotted against mean of histology and physical examination
or MRI. Solid line = identity, dashed line = histologyphysical
examination. Difference between size estimates based on histology and those
based on MRI approaches zero as tumor size increases, suggesting that MRI
becomes more accurate as residual tumor size increases.
|
|

View larger version (151K):
[in a new window]
|
Fig. 3A. 35-year-old woman with invasive ductal carcinoma of left
breast and overestimation by MRI after chemotherapy. Contrast-enhanced
T1-weighted image acquired before initiation of neoadjuvant chemotherapy shows
3.6-cm oval mass with thin rim of peripheral enhancement and heterogeneous
internal enhancement in medial and posterior left breast.
|
|

View larger version (145K):
[in a new window]
|
Fig. 3B. 35-year-old woman with invasive ductal carcinoma of left
breast and overestimation by MRI after chemotherapy. Contrast-enhanced
T1-weighted image acquired after neoadjuvant chemotherapy reveals that
previously shown mass has diminished in size and conspicuity. Residual
abnormality (arrow) measured 1.9 cm in anteroposterior dimension,
although histologic review of lumpectomy specimen showed 0.5-cm nodule
containing viable and necrotic invasive ductal carcinoma. Nonneoplastic breast
tissue submitted contained only "fibrocystic changes."
|
|

View larger version (152K):
[in a new window]
|
Fig. 4A. 75-year-old woman with inflammatory carcinoma of right breast
and persistent segmentally distributed abnormalities on MRI after
chemotherapy. Contrast-enhanced T1-weighted image of right breast acquired
before neoadjuvant chemotherapy shows segmentally distributed region of
abnormal enhancement in upper slightly medial breast. Adjacent skin and areola
are obscured by artifact in this image.
|
|

View larger version (142K):
[in a new window]
|
Fig. 4B. 75-year-old woman with inflammatory carcinoma of right breast
and persistent segmentally distributed abnormalities on MRI after
chemotherapy. Contrast-enhanced T1-weighted image after chemotherapy reveals
persistent multifocal, segmentally distributed enhancement, which measured 6.1
cm in maximum extent. Skin thickening and enhancement in periareolar region
are also evident. Histology review of breast after mastectomy showed 4.0-cm
gross tumor with invasive and in situ ductal carcinoma. However, no multifocal
tumor was shown outside this mass, and both nipple and skin were negative for
malignancy. Nonneoplastic tissue did contain intraductal papilloma and
fibrocystic changes.
|
|

View larger version (67K):
[in a new window]
|
Fig. 5A. 54-year-old woman with high-grade invasive adenocarcinoma of
left breast and true-negative MRI examination after neoadjuvant chemotherapy.
Contrast-enhanced T1-weighted image acquired before neoadjuvant therapy shows
3-cm mass with intense peripheral and heterogeneous internal enhancement.
Abnormal lymph node is also visualized in axilla.
|
|

View larger version (78K):
[in a new window]
|
Fig. 5B. 54-year-old woman with high-grade invasive adenocarcinoma of
left breast and true-negative MRI examination after neoadjuvant chemotherapy.
Contrast-enhanced T1-weighted image after chemotherapy shows complete
resolution of previously seen mass. Histology review of mastectomy specimen
showed area of fibrosis without residual carcinoma.
|
|

View larger version (139K):
[in a new window]
|
Fig. 6A. 39-year-old woman with invasive ductal carcinoma and
false-negative finding on MRI after neoadjuvant chemotherapy.
Contrast-enhanced T1-weighted image acquired before neoadjuvant chemotherapy
shows nonfocal, segmentally distributed areas of enhancement in superior and
posterior breast (arrows).
|
|

View larger version (122K):
[in a new window]
|
Fig. 6B. 39-year-old woman with invasive ductal carcinoma and
false-negative finding on MRI after neoadjuvant chemotherapy.
Contrast-enhanced T1-weighted image suggests area of pathologic enhancement
present before neoadjuvant therapy (arrow) has resolved. At
histology, however, multifocal invasive and in situ ductal carcinoma were
present in seven of 31 blocks from lumpectomy specimen.
|
|

View larger version (131K):
[in a new window]
|
Fig. 7A. 52-year-old woman with extensive left breast carcinoma and
overestimation of residual tumor by MRI after chemotherapy. Contrast-enhanced
T1-weighted image obtained before chemotherapy not only confirms large
irregular mass, but also shows linear enhancement extending toward nipple.
|
|

View larger version (132K):
[in a new window]
|
Fig. 7B. 52-year-old woman with extensive left breast carcinoma and
overestimation of residual tumor by MRI after chemotherapy. Contrast-enhanced
T1-weighted image obtained after chemotherapy shows decreased size and
enhancement of mass, but persistent and extensive linear enhancement in
breast, measuring 6.4 cm in anteroposterior dimension. Histologic evaluation
of mastectomy specimen revealed 3.0-cm invasive and in situ ductal carcinoma.
This size was smaller than predicted by MRI; however, pathologist commented
that microscopic tumor deposits are present diffusely. It is very likely,
therefore, that standard histologic size determination underestimated actual
disease extent.
|
|

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2003 by the American Roentgen Ray Society.